Avita Medical Awarded US$7.96m in BARDA Extension Deal
Northridge, CA, Perth, Australia and London, United Kingdom – 27 June 2016 Link here.
Nexvet Presents Expanded Positive Clinical Data for Ranevetmab (NV-01) and Frunevetmab (NV-02) at ACVIM
/in Pharmamark, Portfolio CompaniesDUBLIN, Ireland, June 09, 2016 (GLOBE NEWSWIRE)- Nexvet Biopharma (Nasdaq:NVET), a veterinary biologic therapeutics company, is today presenting expanded results regarding completed clinical studies for ranevetmab (or “NV-01”) and frunevetmab (or “NV-02”) to veterinarians and veterinary key opinion leaders at a Nexvet-hosted seminar at the American College of Veterinary Internal Medicine (ACVIM) Forum today in […]
Nexvet Announces Opening of Manufacturing Facility and Production Milestone Achievement
/in Pharmamark, Portfolio CompaniesDUBLIN, Ireland, June 03, 2016 (GLOBE NEWSWIRE) – Nexvet Biopharma (Nasdaq:NVET), a veterinary biologic therapeutics developer, today announced the official opening of BioNua Limited, its veterinary biologics manufacturing facility in Tullamore, Ireland, as well as in-house production of its first clinical trial batch of NV-02 from a 200 liter production bioreactor. NV-02 is Nexvet’s monoclonal […]
AVH – ReCell Reduces Long-Term Scarring and Itching Outcomes in Pediatric Burns Treatment
/in Portfolio CompaniesNorthridge, CA and Cambridge, UK, 6 May 2016 – Link here.
Rex Bionics inks US Army deal to test robot exoskeletons with amputees
/in Rex Bionicshttps://www.stuff.co.nz/business/better-business/78700698/Rex-Bionics-inks-US-Army-deal-to-test-robot-exoskeletons-with-amputees Auckland robotics company Rex Bionics has signed a deal with the United States Army to help amputee soldiers get back on their feet. The special agreement means the firm, which develops robotic suits and legs, will be able to test out its developing “Rex Suit” technology on hundreds of maimed veterans Rex Bionics has spent many years and millions […]
AmpliPhi Biosciences Reports First Quarter 2016 Financial Results and Provides Corporate Update
/in Portfolio CompaniesSAN DIEGO, May 12, 2016 – Link here. AmpliPhi Biosciences Corporation (NYSEMKT: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug-resistant infections, today announced its financial results for the first quarter ended March 31, 2016. “We have made significant progress in 2016, effectively executing on our clinical development and business […]
Nexvet Reports Financial Results for Third Quarter of Fiscal Year 2016
/in Pharmamark, Portfolio CompaniesDUBLIN, Ireland, May 12, 2016 (GLOBE NEWSWIRE) — Link here. Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, today announced its financial results for the three and nine-month periods ended March 31, 2016. Recent company highlights include: Advanced clinical development and regulatory preparations for ranevetmab (NV-01), for the control of pain associated with osteoarthritis in dogs […]
Avita’s ReNovaCell™ Offers Advantages in Skin Repigmentation of Burn Scars
/in Portfolio CompaniesNorthridge, CA, Perth, Australia and Cambridge, UK, 9 May 2016. Link here.
Avita Medical’s ReCell Technology Demonstrated at Vitiligo Conferences in China
/in Portfolio CompaniesNorthridge, CA, USA, Perth, Australia and Cambridge, United Kingdom, 3 May 2016 – Link here.
Nexvet and Zenoaq Announce PD-1 mAb Candidate for Canine Cancer & USDA Regulatory Jurisdiction Confirmed
/in Pharmamark, Portfolio CompaniesDUBLIN, Ireland, May 02, 2016 (GLOBE NEWSWIRE) – Link here – Nexvet Biopharma (Nasdaq:NVET), a veterinary biologics developer, and Zenoaq (Nippon Zenyaku Kogyo Co., Ltd.), a leading Japanese animal health company, announced today their research and development collaboration has yielded fully caninized, or ‘100% dog’, monoclonal antibodies (mAbs) that bind and potently inhibit the immuno-oncology […]